science 37 uses advanced telemedicine technology and patient-centric innovative networked clinical research models to rapidly accelerate biomedical discovery and bring down the costs of clinical trials. in addition to our own researchers, we also work closely with top physician-scientists and leading telemedicine companies. s37 offers full support and end-to-end services for networked clinical trials. if you are an investigator, an inventor, a small biotech company or a large pharmaceutical company, we can help you achieve your clinical trial goals faster and easier than ever before. based in los angeles, we are focused on the development of networked patient-centric models for clinical research to rapidly accelerate biomedical discovery. we leverage partnerships with national mobile nursing companies, pharmacy chains, patient advocacy groups, virtual e-consenting, mobile devices, and other technology companies to maximize efficiency. then, using design-thinking principles and rapid pr
Company profile
Ticker
SNCE
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Incyte • Zymergen • OmniAb ...
Former names
Lifesci Acquisition II Corp.
SEC CIK
Corporate docs
Subsidiaries
Science 37, Inc. • Diversity in Clinical Research • Science 37 s.r.o • Science 37 UK Limited ...
IRS number
844278203
SNCE stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
22 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
EFFECT
Notice of effectiveness
15 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Mar 24
POS AM
Prospectus update (post-effective amendment)
12 Mar 24
POS AM
Prospectus update (post-effective amendment)
12 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
12 Mar 24
Transcripts
SNCE
Earnings call transcript
2023 Q3
7 Nov 23
SNCE
Earnings call transcript
2023 Q2
8 Aug 23
SNCE
Earnings call transcript
2023 Q1
15 May 23
SNCE
Earnings call transcript
2022 Q4
6 Mar 23
SNCE
Earnings call transcript
2022 Q3
11 Nov 22
SNCE
Earnings call transcript
2022 Q2
15 Aug 22
SNCE
Earnings call transcript
2022 Q1
9 May 22
SNCE
Earnings call transcript
2021 Q4
22 Mar 22
SNCE
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
4
Change in insider ownership
14 Mar 24
4
Change in insider ownership
14 Mar 24
3/A
Initial statement of insider ownership (amended)
14 Mar 24
SC 13D/A
THERMO FISHER SCIENTIFIC INC.
14 Mar 24
4
Robert C. Faulkner
13 Mar 24
4
Jeremy Green
13 Mar 24
SC 13D/A
Redmile Group, LLC
13 Mar 24
4
Michael Shipton
12 Mar 24
4
Jonathan Cotliar
12 Mar 24
4
Darcy Forman
12 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Jun 21 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 56.41 mm | 56.41 mm | 56.41 mm | 56.41 mm | 56.41 mm | 56.41 mm |
Cash burn (monthly) | 2.87 mm | 6.15 mm | 4.85 mm | 10.80 mm | 133.33 k | 4.02 mm |
Cash used (since last report) | 19.85 mm | 42.62 mm | 33.58 mm | 74.78 mm | 923.54 k | 27.82 mm |
Cash remaining | 36.56 mm | 13.79 mm | 22.83 mm | -18.38 mm | 55.48 mm | 28.59 mm |
Runway (months of cash) | 12.8 | 2.2 | 4.7 | -1.7 | 416.1 | 7.1 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 1 |
Closed positions | 43 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 421.63 mm |
Total shares | 51.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TMO Thermo Fisher Scientific | 17.38 mm | $191.70 mm |
PPD PPD | 17.38 mm | $0.00 |
Lux Capital Management | 12.25 mm | $69.33 mm |
LifeSci | 4.92 mm | $0.00 |
Kingswood Wealth Advisors | 29.73 k | $158.73 mm |
M&R Capital Management | 350.00 | $1.87 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Mar 24 | Jonathan Cotliar | Common Stock | Sale back to company | Dispose D | No | No | 5.75 | 12,864 | 73.97 k | 0 |
12 Mar 24 | Jonathan Cotliar | Common Stock | Dispose U | No | No | 5.75 | 41,891 | 240.87 k | 0 | |
12 Mar 24 | Jonathan Cotliar | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 8 | 7,944 | 63.55 k | 0 |
12 Mar 24 | Jonathan Cotliar | Earn-Out Right Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,385 | 0.00 | 0 |
12 Mar 24 | Jonathan Cotliar | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 23,088 | 0.00 | 0 |
12 Mar 24 | Darcy Forman | Common Stock | Sale back to company | Dispose D | No | No | 5.75 | 24,644 | 141.70 k | 0 |
12 Mar 24 | Darcy Forman | Common Stock | Dispose U | No | No | 5.75 | 15,753 | 90.58 k | 0 | |
12 Mar 24 | Darcy Forman | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 5.51 | 3,404 | 18.76 k | 0 |
12 Mar 24 | Darcy Forman | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16.31 | 6,807 | 111.02 k | 0 |
12 Mar 24 | Darcy Forman | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.93 | 4,680 | 37.11 k | 0 |
News
Baird Downgrades Science 37 Hldgs to Neutral, Announces $5.75 Price Target
30 Jan 24
Crude Oil Down Over 1%; Science 37 Holdings Shares Spike Higher
29 Jan 24
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
29 Jan 24
Craig-Hallum Downgrades Science 37 Hldgs to Hold
29 Jan 24
Press releases
eMed completes tender offer for all outstanding shares of Science 37
12 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CHRD, TCN, SNCE
27 Feb 24
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
27 Feb 24
Kuehn Law Encourages DFS, SNCE, HRT, and IONM Investors to Contact Law Firm
19 Feb 24
Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?
16 Feb 24